清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

128TiP A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)

医学 贝伐单抗 结直肠癌 内科学 临床研究阶段 肿瘤科 癌症研究 癌症 化疗
作者
Ren Lin,Sihai Zhao,Liang Su,Yong Sang Hong,Jie Luo,Wang Yongmei,Sihai Dave Zhao
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1519-S1519
标识
DOI:10.1016/j.annonc.2023.10.263
摘要

Immune-checkpoint inhibitors (ICI) show modest activity and efficacy in patients with MSS mCRC and pMMR. A recent trial of botensilimab (next-generation anti–CTLA-4 antibody) + balstilimab (anti-PD-1 antibody) for heavily pretreated pMMR/MSS mCRC reported promising results. Cadonilimab is a humanized bi-specific antibody that targets both PD-1 and CTLA-4. Its higher binding avidity in a tumor-like setting and Fc-null design may increase drug retention in tumors and improve safety. A more intensive chemotherapy, FOLFOXIRI + bevacizumab, can enhance the antitumor effect of ICI by increasing tumor immunogenicity. AtezoTRIBE, a phase II study, showed that adding atezolizumab to first-line FOLFOXIRI + bevacizumab might improve progression-free survival (PFS) in patients with mCRC. Therefore, in this study we aim to investigate the efficacy and safety of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for patients with unresectable pMMR/MSS mCRC. This is a multicenter single arm phase II study. Eligibility criteria include: histologically or cytologically confirmed pMMR/MSS mCRC; age 18-75 years; naive to systemic treatment in the metastatic setting; at least 1 measurable lesion according to RECIST 1.1; ECOG PS 0-1; and adequate organ function. Patients with high microsatellite instability (MSI-H) tumors and those who previously received immunotherapy are excluded. Twenty eligible participants will receive FOLFOXIRI (intravenous [i.v.] irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2400 mg/m2 as a 48-h infusion) + bevacizumab 5 mg/kg i.v. and cadonilimab 6 mg/kg i.v. Treatment is administered for up to twelve 14-day cycles followed by maintenance with fluorouracil and leucovorin (or capecitabine) + bevacizumab and cadonilimab for a total of 52 weeks or until disease progression, unacceptable adverse events, or consent withdrawal. The primary endpoint is objective response rate per RECIST 1.1. Secondary endpoints are PFS, overall survival, and safety. Enrollment is ongoing. NCT05839470. The authors. Akeso, Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
优美的明辉完成签到 ,获得积分10
5秒前
帅气的沧海完成签到 ,获得积分10
27秒前
jlwang完成签到,获得积分10
35秒前
52秒前
彦嘉发布了新的文献求助10
57秒前
宇文雨文完成签到 ,获得积分10
1分钟前
1分钟前
末末完成签到 ,获得积分10
1分钟前
1分钟前
ceeray23发布了新的文献求助20
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
笨笨完成签到 ,获得积分10
1分钟前
芒芒发paper完成签到 ,获得积分10
2分钟前
顺心蜜粉发布了新的文献求助30
2分钟前
顺心蜜粉完成签到,获得积分10
2分钟前
2分钟前
CC发布了新的文献求助10
2分钟前
淞淞于我完成签到 ,获得积分10
2分钟前
Jenny发布了新的文献求助50
2分钟前
CC完成签到,获得积分10
2分钟前
天天开心完成签到 ,获得积分10
3分钟前
Qian完成签到 ,获得积分10
3分钟前
4分钟前
玄之又玄完成签到,获得积分10
4分钟前
糯米团的完成签到 ,获得积分10
4分钟前
爆米花应助ceeray23采纳,获得20
4分钟前
爆米花应助彦嘉采纳,获得10
4分钟前
5分钟前
ceeray23发布了新的文献求助20
5分钟前
zpc猪猪完成签到,获得积分10
5分钟前
Jenny发布了新的文献求助50
5分钟前
香蕉觅云应助ceeray23采纳,获得20
5分钟前
hoshi完成签到 ,获得积分10
5分钟前
woxinyouyou完成签到,获得积分0
5分钟前
思源应助方俊驰采纳,获得10
5分钟前
yuyuyu完成签到 ,获得积分10
5分钟前
6分钟前
方俊驰发布了新的文献求助10
6分钟前
方俊驰完成签到,获得积分10
6分钟前
6分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990568
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234